|
RCBTB1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.72980029878556E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.36759999997049E-07 |
| Normal-vs-Stage2 |
8.047100E-04 |
| Normal-vs-Stage3 |
1.38280054073903E-10 |
| Normal-vs-Stage4 |
1.12019999942703E-08 |
| Stage1-vs-Stage2 |
5.756200E-01 |
| Stage1-vs-Stage3 |
1.069780E-02 |
| Stage1-vs-Stage4 |
2.550100E-02 |
| Stage2-vs-Stage3 |
1.803740E-02 |
| Stage2-vs-Stage4 |
1.946230E-02 |
| Stage3-vs-Stage4 |
7.506800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.67319524691356E-11 |
| Normal-vs-AfricanAmerican |
7.995100E-03 |
| Normal-vs-Asian |
3.48419999995908E-06 |
| Caucasian-vs-AfricanAmerican |
1.730990E-01 |
| Caucasian-vs-Asian |
5.651400E-01 |
| AfricanAmerican-vs-Asian |
3.825200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.89359999692007E-08 |
| Normal-vs-Female |
3.87669996104734E-09 |
| Male-vs-Female |
8.342200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.51817999999304E-05 |
| Normal-vs-Age(41-60Yrs) |
2.89110002604787E-09 |
| Normal-vs-Age(61-80Yrs) |
1.51600000330987E-08 |
| Normal-vs-Age(81-100Yrs) |
1.664660E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.171220E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.288000E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.310170E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.824800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.522600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.607400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.576600E-04 |
| Classical-VS-Follicular |
3.649900E-04 |
| Classical-VS-Other |
5.752800E-01 |
| Classical-VS-Normal |
1.05709996311987E-10 |
| Tall-VS-Follicular |
6.25589999803111E-08 |
| Tall-VS-Other |
2.100200E-02 |
| Tall-VS-Normal |
3.44959616427332E-11 |
| Follicular-VS-Other |
4.775200E-01 |
| Follicular-VS-Normal |
2.966300E-02 |
| Other-VS-Normal |
6.866500E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.78589999963752E-07 |
| Normal-vs-N1 |
1.91649999981003E-07 |
| N0-vs-N1 |
7.606300E-02 |
|
|
